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Lorraine Collins:The demand for accountability is
ratcheting up. Methadone programs may find them-
selves having to be increasingly accountable.
William Cornely:With respect to retention of patients
in opioid treatment, most drug-free programs have
already made the transition to viewing the patient as
a customer who must be retained, and their experi-
ence may be helpful to methadone programs.
What other outcomes, besides retention, should
be considered for accountability? For example, what
about having someone off methadone in a year or 
2 years, or having lower incidence of AIDS?
Christine Grella: Ideally, methadone programs would
target a range of outcomes, including use of opioids
and other drugs, alcohol use, and then issues such as
housing, unemployment, and general psychosocial
functioning. A troubling issue that I saw first-hand
while working on a study in a methadone clinic is that
much of the patients’ ability to respond to treatment
was related to issues in their communities and to things
like whether they continued to live with a substance
abuser. These environmental issues are a huge deter-
minant of outcomes and completely beyond our 
control.
Grella: Jackson’s call for partnership—informing the
treatment staff of current research and inviting researchers
to work with providers in testing different approaches
to improving delivery of treatment—is excellent.
He is absolutely right, too, in saying we need more
research on how organizations can change to imple-
ment different treatment practices. A potential research
question would be, ‘What program characteristics are
associated with the ability to implement effective prac-
tices?’ Jackson cites one example: a study showing that
attitudes and experiences of program directors in
methadone programs made a difference.
Collins: Many programs have staff members who work
there because of their experiences recovering from sub-
stance abuse and who have an understandable bias
toward whatever treatment regimen was successful for
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them. Those perspectives are now being challenged
or questioned by the emphasis on accountability. In
the future, treatment personnel may have to come
from other backgrounds, with professional rather than
experiential training. Research might look at the ques-
tion, ‘How well are staff members with each kind of
background able to perform as drug abuse treat-
ment providers?’
Grella: I was intrigued with the author’s suggestion
that the research community can give more guidance
on different ways to train the program staff. I think
this is especially important in OTP facilities where
the staff—especially those who have worked a long
time—may have strong beliefs about how effective
the treatment is and what they can accomplish with
the patients they see. We really need to test different
approaches to working with staff members to upgrade
their skills and deal with their resistance to change.
Collins:The use of treatment manuals and other mate-
rials to disseminate actual treatment protocols is going
to be crucial for raising the level of staff knowledge.
The large multisite research studies are already start-
ing to do this. The manuals walk practitioners through
the study protocols step by step. For example, here
is a new assessment instrument, here is how you score
it, here are some ways of intervening with patients
with each possible score.
To some extent, I think Jackson sees researchers
as able to do more than we actually can. Researchers
will not be able to influence all the State regulations
and policies that affect credentialing. With respect to
salary structures, we will not be able to do much beyond
saying that with better education and better pay, you
might have a more effective staff. As to the issue of
enhancing the ability of agencies to perform sur-
vival analysis, even universities have difficulty find-
ing staff to do survival analysis.
Grella:When researchers work with treatment providers,
our methods have to be objective, but we also want
the treatment to be successful, and partnership is
important for that reason.
Cornely:This issue of noncompliant—for lack of a
better word—patients is one that programs grapple
with all the time. When you have to make a decision
about keeping someone in treatment who continues
to use drugs, especially in drug-free treatment, you
walk a fine line between maintaining the integrity of
the program and helping the individual. In our pro-
gram we will usually retain a patient who uses drugs
and help them get through the relapse, intensify serv-
ices, and those sorts of things. Some other programs
are very rigid: If you use, you are kicked out.
Generally, the belief is that good treatment means
increasing treatment, rather than withdrawing it, when
patients continue to use or relapse. Jackson suggests
that a wider range of treatment options might be the
answer for some nonresponding individuals. We can
certainly design a study where we have different lev-
els of intensity—high, enhanced, etc. But given the
reality in which these programs function, with their
limited resources, how are they going to implement
the programs?
Grella:The research is very clear that individuals in
methadone therapy who use cocaine or alcohol have
relatively poor response to treatment. We can design
studies to look at cocaine-reduction protocols in
methadone programs, but the degree to which com-
munity OTPs can implement them is going to vary
widely. We keep coming back to the issues of resources
and feasibility.
Collins: A lot of programs aren’t focusing enough on
mental health issues as they relate to substance abuse.
Maybe someone is not responding well to methadone
because of other psychiatric problems that are not
being addressed by the program. We probably need
broader assessments. Research can definitely help with
that. One research-based model is [Prochaska and Di
Clemente’s] ‘Stages of Change,’ which has been applied
to drug abuse. Stages of Change looks at where peo-
ple are along a continuum that goes from precon-
templation [not really considering the life changes
that treatment will require], through contemplation
[of committing to the changes], to action, and so on.
If somebody is in the precontemplation stage, it’s not
the right time to jump into treatment, but there might
be some other activities he or she could engage in to
move the process along.&
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